(Q34213649)

English

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

S. Vincent Rajkumar

17

object named as

S V Rajkumar

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

S K Kumar

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

I Flinn

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

S J Noga

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

P Hari

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

R Rifkin

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

N Callander

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

M Bhandari

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

J L Wolf

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

C Gasparetto

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A Krishnan

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

D Grosman

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

J Glass

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

E A Sahovic

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

H Shi

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

I J Webb

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

P G Richardson

16

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

27 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1350-1356

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

5 July 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

21 January 2018

Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

28 October 2018

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2957585

28 October 2018

Lenalidomide and venous thrombosis in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20508619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically relevant end points and new drug approvals for myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20508619

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Many facets of bortezomib resistance/susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.116

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2010.116

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34213649&oldid=2196388204"